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2748Have the authors investigated in their post-hoc analysis (1)
whether HDL-C levels were associated with alterations in whole
blood count or other established immune-inﬂammatory markers,
such as CRP? Can the whole blood count or CRP levels limit the
power of prediction of HDL-C when adjusted for inﬂammatory
markers?
As a further speculation, the limited clinical beneﬁt of niacin or
cholesteryl ester transfer protein inhibitors, despite effective in-
creases in HDL-C levels (4,11), could be associated with an
inconsistent enhancing effect on immune-inﬂammatory response
or with the modulation of HDL subclasses unable to tune immune
response during atherogenesis.*Enrico Ammirati, MD
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367:2089–99.Mechanisms Explaining
the Relationship Between
Metabolically Healthy Obesity
and Cardiovascular RiskRecently, much interest has been given to the novel concept of
metabolically healthy obesity (MHO). It could help to direct the
limited resources that are available for prevention of metabolic
diseases to the people at highest risk (1). Mørkedal et al. (2) now
showed that individuals with MHO are not at increased risk of
acute myocardial infarction (AMI) compared with normal-weight,
metabolically healthy subjects. In contrast, they have an increased
incidence of heart failure (HF) (2). Lavie et al. (3) convincingly
discussed mechanisms, explaining why obesity itself, and not
necessarily only metabolic abnormalities such as hypertension,
dyslipidemia, hyperglycemia, and subclinical inﬂammation, has an
impact on the development of HF. Most recently, a meta-analysis
questioned the concept of MHO for its relevance for cardiovascular
events (4). The study of Mørkedal et al. now can show that it is
necessary to separate the predictive effects of MHO on AMI and
HF when it comes to the prediction of cardiovascular disease.
The study by Mørkedal et al. (2) cannot provide mechanisms
explaining the lower risk of AMI in those with MHO compared
with subjects with metabolically unhealthy obesity. We could show
that MHO is associated with a moderately reduced visceral fat
mass, but, more importantly, with a largely reduced liver fat content
(5). We also provided evidence that genetic variability in the adi-
ponectin receptor 1 gene determines the prevalence of MHO and
that MHO correlates with lower levels of the liver-secreted
glycoprotein fetuin-A (5). Particularly lower production of this
proinﬂammatory hepatokine, which affects glucose and lipid
metabolism and induces subclinical inﬂammation (6,7), may
explain the lower risk of AMI in MHO.
Regarding preventive strategies in MHO, Mørkedal et al. (2)
refer to a small study indicating that lifestyle intervention may
decrease insulin sensitivity and thus be harmful for people with this
condition (8). However, we could show in a larger study that
visceral fat mass decreased and insulin sensitivity remained high
during a lifestyle intervention in subjects with MHO (9).
The concept of MHO has gained much interest in the scientiﬁc
community. However, because of its complex nature and the not
fully understood mechanisms involved in the causes and conse-
quences of MHO, it is very important to carefully deal with this
popular concept when it comes to the prediction and prevention of
metabolic diseases.*Norbert Stefan, MD
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